5Lba Everolimus in advanced nonfunctional neuroendocrine tumors (Net) of lung or gastrointestinal (Gi) origin: Efficacy and safety results from the placebo-controlled, double-blind, multicenter, Phase 3 Radiant-4 study
Yao, J.; Fazio, N.; Singh, S.; Buzzoni, R.; Carnaghi, C.; Wolin, E.; Tomasek, J.; Raderer, M.; Lahner, H.; Voi, M.; Pacaud, L.; Lincy, J.; Sachs, C.; Valle, J.; Delle Fave, G.
European Journal of Cancer 51: S709-S710
2015
ISSN/ISBN: 0959-8049
DOI: 10.1016/s0959-8049(16)31928-1
Accession: 067138899
PDF emailed within 0-6 h: $19.90
Related References
Pavel, M.E.; Singh, S.; Strosberg, J.R.; Bubuteishvili-Pacaud, L.; Degtyarev, E.; Neary, M.P.; Carnaghi, C.; Tomasek, J.; Wolin, E.; Raderer, M.; Lahner, H.; Valle, J.W.; Pommier, R.; Van Cutsem, E.; Tesselaar, M.E.T.; Fave, G.D.; Buzzoni, R.; Hunger, M.; Eriksson, J.; Cella, D.; Ricci, J.-F.ço.; Fazio, N.; Kulke, M.H.; Yao, J.C. 2017: Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial LANCET. Oncology 18(10): 1411-14222016: Everolimus for Advanced, Progressive, Nonfunctional Neuroendocrine Tumors (NET) of the Gastrointestinal (GI) Tract: Efficacy and Safety From a RADIANT-4 Subgroup Analysis Clinical Advances in Hematology and Oncology: H&o 14(5 Suppl. 7): 11-13
Yao, J.; Fazio, N.; Buzzoni, R.; Delle Fave, G.; Tesselaar, M.; Wolin, E.; Van Cutsem, E.; Tomassetti, P.; Strosberg, J.; Voi, M.; Pacaud, L.; Ridolfi, A.; Singh, S.; Pavel, M.; Kulke, M. 2016: ORAL02.02: Efficacy and Safety of Everolimus in Advanced, Progressive, Nonfunctional Neuroendocrine Tumors (NET) of the Lung: RADIANT-4 Subgroup Analysis: Topic: Medical Oncology Journal of Thoracic Oncology 11(11s): S253
Yao, J.C.; Singh, S.; Wolin, E.; Voi, M.; Pacaud, L.B.; Lincy, J.; Sachs, C.; Valle, J.W.; Van Cutsem, E.; Shimada, Y.; Oh, D.-Y. 2015: 134Oradiant-4: Efficacy and safety of everolimus in advanced, nonfunctional neuroendocrine tumors (Net) of the lung or gastrointestinal (Gi) tract Annals of Oncology 26(Suppl 9): ix 40.1-ix 40
Yao, J.C.; Fazio, N.; Singh, S.; Buzzoni, R.; Carnaghi, C.; Wolin, E.; Tomasek, J.; Raderer, M.; Lahner, H.; Voi, M.; Pacaud, L.B.; Rouyrre, N.; Sachs, C.; Valle, J.W.; Fave, G.D.; Van Cutsem, E.; Tesselaar, M.; Shimada, Y.; Oh, D.-Y.; Strosberg, J.; Kulke, M.H.; Pavel, M.E. 2016: Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study Lancet 387(10022): 968-977
Yao, J.C.; Oh, D.-Y.; Qian, J.; Park, Y.S.; Herbst, F.; Ridolfi, A.; Izquierdo, M.; Ito, T.; Jia, L.; Komoto, I.; Sriuranpong, V.; Shimada, Y. 2019: Everolimus for the treatment of advanced gastrointestinal or lung nonfunctional neuroendocrine tumors in East Asian patients: a subgroup analysis of the RADIANT-4 study Oncotargets and Therapy 12: 1717-1728
Fazio, N.; Granberg, D.; Grossman, A.; Saletan, S.; Klimovsky, J.; Panneerselvam, A.; Wolin, E.M. 2013: Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: analysis of the phase 3, randomized, placebo-controlled RADIANT-2 study Chest 143(4): 955-962
Pavel, M.E.; Baudin, E.; Öberg, K.E.; Hainsworth, J.D.; Voi, M.; Rouyrre, N.; Peeters, M.; Gross, D.J.; Yao, J.C. 2019: Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study Annals of Oncology: Official Journal of the European Society for Medical Oncology 30(12): 2010
Pavel, M.E.; Baudin, E.; Öberg, K.E.; Hainsworth, J.D.; Voi, M.; Rouyrre, N.; Peeters, M.; Gross, D.J.; Yao, J.C. 2017: Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study Annals of Oncology: Official Journal of the European Society for Medical Oncology 28(7): 1569-1575
Pavel, M.E.; Baudin, E.; Öberg, K.E.; Hainsworth, J.D.; Voi, M.; Rouyrre, N.; Peeters, M.; Gross, D.J.; Yao, J.C. 2019: Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study Annals of Oncology: Official Journal of the European Society for Medical Oncology 30(12): 2010
Stein Gold, L.; Papp, K.; Pariser, D.; Green, L.; Bhatia, N.; Sofen, H.; Albrecht, L.; Gooderham, M.; Chen, M.; Paris, M.; Wang, Y.; Callis Duffin, K. 2022: Efficacy and safety of apremilast in patients with mild-to-moderate plaque psoriasis: Results of a phase 3, multicenter, randomized, double-blind, placebo-controlled trial Journal of the American Academy of Dermatology 86(1): 77-85
Motzer, R.J.; Escudier, B.; Oudard, S.ép.; Hutson, T.E.; Porta, C.; Bracarda, S.; Grünwald, V.; Thompson, J.A.; Figlin, R.A.; Hollaender, N.; Urbanowitz, G.; Berg, W.J.; Kay, A.; Lebwohl, D.; Ravaud, A.; Davis, I.; Gurney, H.; Pittman, K.; Goldstein, D.; Mainwaring, P.; Knox, J.; Ades, S.; Cheng, T.; Hotte, S.; Ko, Y.-J.; MacKenzie, M.; North, S.; Caty, A.; Rolland, F.; Chevreau, C.; Duclos, B.; Negrier, S.; Gschwend, J.; Albers, P.; Bergmann, L.; Beck, J.; Bajetta, E.; Passalacqua, R.; Sternberg, C.; Boccardo, F.; Carteni, G.; Conte, P.F.; Shinohara, N.; Tsuchiya, N.; Akaza, H.; Fujimoto, H.; Niwakawa, M.; Uemura, H.; Kanayama, H.; Eto, M.; Sumiyoshi, Y.; Tsukamoto, T.; Usami, M.; Terai, A.; Hamamoto, Y.; Maruoka, M.; Osanto, S.; Van Her 2008: Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase IIi trial Lancet 372(9637): 449-456
Kibel, A.S. 2009: Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial Yearbook of Urology 2009: 96-98
Van Voorhees, A.S.; Stein Gold, L.; Lebwohl, M.; Strober, B.; Lynde, C.; Tyring, S.; Cauthen, A.; Sofen, H.; Zhang, Z.; Paris, M.; Wang, Y. 2020: Efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: Results of a phase 3b, multicenter, randomized, placebo-controlled, double-blind study Journal of the American Academy of Dermatology 83(1): 96-103
Itoh, H.; Ishii, K.; Shigeta, N.; Itakura, A.; Hamada, H.; Nagamatsu, T.; Ishida, T.; Bungyoku, Y.; Falahati, A.; Tomisaka, M.; Kitamura, M. 2021: Efficacy and safety of controlled-release dinoprostone vaginal delivery system (PROPESS) in Japanese pregnant women requiring cervical ripening: Results from a multicenter, randomized, double-blind, placebo-controlled phase IIi study Journal of Obstetrics and Gynaecology Research 47(1): 216-225